{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA\/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-1-dose-escalation-study-to-investigate-the-safety-efficacy-pharmacokinetics-and-pharmacodynamic-activity-of-cln-619-anti-mica-micb-antibody-alone-and-in-combination-with-pembrolizumab-in\/#breadcrumbitem"}]}